Neurological Sciences

, Volume 25, Issue 6, pp 307–310

Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study

Authors

    • Department of NeurologyP. A. Micone Hospital
  • G. Brichetto
    • Department of Neurosciences, Ophthalmology and GeneticsUniversity of Genoa
  • M. A. Battaglia
    • Department of Physiopathology, Experimental Medicine and Public HealthUniversity of Siena
  • M. Messmer Uccelli
    • Italian Multiple Sclerosis Society
  • G. L. Mancardi
    • Department of Neurosciences, Ophthalmology and GeneticsUniversity of Genoa
ORIGINAL

DOI: 10.1007/s10072-004-0362-9

Cite this article as:
Solaro, C., Brichetto, G., Battaglia, M.A. et al. Neurol Sci (2005) 25: 307. doi:10.1007/s10072-004-0362-9

Abstract

Neuropathic pain and paroxysmal symptoms are common in multiple sclerosis (MS) patients, although no double-blind clinical trial has been conducted to support antiepileptic medications (AED) use in MS. The aim of the study was to evaluate the frequency of AED utilisation and reported adverse events, in a cohort of MS patients. For a period of 3 years the rationale for prescribing AED, adverse effects, treatment duration and reasons for discontinuation were recorded in a database. Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse. Gabapentin (GBP) was prescribed in 94 patients, with adverse effects reported in 16 cases and in one case mimicked a relapse. Lamotrigine (LMT) was prescribed in 22 patients, with adverse effects reported in 4 cases, none mimicking a relapse. The present study found a significantly higher incidence of adverse effects in patients treated with CBZ, with a high rate of discontinuation at low dosages and episodes of evident worsening of neurological functioning compared to GBP or LMT.

Key words

Antiepileptic medicationsAdverse effectsCarbamazepineGabapentinLamotrigine

Copyright information

© Springer-Verlag Italia 2005